The case study from Switzerland that was included with @hottod’s post could have been overlooked by some as, with her usual thoroughness, it was amongst a number of other supporting references included by her.
I suggest all holders give themselves a treat and read it!
https://www.sciencedirect.com/science/article/pii/S2468912221000213
If you’re really short of time, at least read paragraph 3.1 about BTM.
One remarkable aspect is that the patient was admitted on the very day BTM became available in Switzerland.
The case study from Switzerland that was included with @hottod’s...
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.09 |
Change
0.080(3.98%) |
Mkt cap ! $1.442B | |||
| Open | High | Low | Value | Volume |
| $2.03 | $2.09 | $2.03 | $1.476M | 710.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5010 | $2.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.09 | 135016 | 10 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.09 |
Change
0.080 ( 3.33 %) |
||||
| Open | High | Low | Volume | ||
| $2.03 | $2.09 | $2.03 | 302647 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| PNV (ASX) Chart |